Alkem Laboratories Sees Sharp Open Interest Surge Amid Mixed Technical Signals

Open Interest and Volume Dynamics

On 24 Mar 2026, Alkem Laboratories (symbol: ALKEM) recorded an open interest (OI) of 16,278 contracts, up from 13,297 the previous day, marking an increase of 2,981 contracts or 22.42%. This notable rise in OI was accompanied by a futures volume of 9,370 contracts, indicating active participation in the derivatives market. The futures value stood at approximately ₹44,557 lakhs, while the options segment exhibited a substantial notional value of ₹1,685 crore, culminating in a total derivatives market value of ₹44,684 lakhs for the stock.

The underlying stock price closed at ₹5,298, having touched an intraday high of ₹5,302, outperforming its sector by 1.76% and the Sensex by 0.88%. The stock delivered a 1-day return of 2.65%, surpassing the Pharmaceuticals & Biotechnology sector’s 1.03% gain and the Sensex’s 1.77% rise. However, despite this outperformance, Alkem Laboratories remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a persistent downtrend in the medium to long term.

Market Positioning and Investor Sentiment

The surge in open interest alongside rising volumes suggests that market participants are actively repositioning themselves, possibly anticipating a directional move. The increase in OI typically reflects fresh money entering the market, which can either reinforce the current trend or signal an impending reversal depending on price action.

Interestingly, delivery volumes have declined sharply, with the delivery volume on 23 Mar falling by 50.02% to 51.71k shares compared to the 5-day average. This drop in investor participation at the cash level contrasts with the heightened activity in the derivatives market, implying that traders may be favouring short-term speculative positions over long-term holdings.

Given the stock’s mid-cap status with a market capitalisation of ₹63,142.28 crores, liquidity remains adequate for sizeable trades, with a 2% threshold of the 5-day average traded value supporting trade sizes up to ₹1.52 crore. This liquidity profile facilitates active derivatives trading without significant market impact.

Directional Bets and Derivatives Strategy

The sharp increase in open interest, coupled with rising futures volume, points to a growing consensus among traders about a potential directional move in Alkem Laboratories. However, the stock’s position below all key moving averages tempers bullish enthusiasm, suggesting that any upside may be met with resistance.

Options market data, with an options value exceeding ₹1,685 crore, indicates substantial hedging and speculative activity. The elevated options notional value often reflects a mix of protective puts and bullish calls, signalling that market participants are positioning for volatility rather than a clear directional trend.

Given the Mojo Score of 47.0 and a recent downgrade from Hold to Sell on 13 Mar 2026, the stock’s fundamental outlook remains cautious. The downgrade reflects concerns over earnings momentum and sector headwinds, which may be influencing the cautious stance of institutional investors despite short-term price gains.

Technical and Fundamental Outlook

Technically, Alkem Laboratories’ failure to breach its moving averages suggests that the recent price rally may be a corrective bounce rather than a sustained uptrend. The falling delivery volumes reinforce this view, indicating limited conviction among long-term investors.

Fundamentally, the pharmaceutical sector continues to face challenges including regulatory scrutiny and pricing pressures, which may weigh on Alkem’s earnings growth. The mid-cap classification also implies higher volatility compared to large-cap peers, necessitating cautious positioning.

Investor Takeaway

Investors should approach Alkem Laboratories with caution given the mixed signals from derivatives and cash markets. The surge in open interest and futures volume suggests increased speculative interest, but the stock’s technical weakness and fundamental downgrade advise prudence.

Traders may consider monitoring the stock’s ability to reclaim key moving averages as a confirmation of a sustained uptrend. Meanwhile, the elevated options activity points to expectations of volatility, which could present trading opportunities for those comfortable with derivatives strategies.

Overall, Alkem Laboratories remains a mid-cap stock with moderate liquidity and active derivatives participation, but current market positioning and fundamental assessments favour a cautious stance rather than aggressive accumulation.

Summary of Key Metrics

Market Cap: ₹63,142.28 crores (Mid Cap)
Mojo Score: 47.0 (Sell, downgraded from Hold on 13 Mar 2026)
Open Interest Change: +22.42% (from 13,297 to 16,278 contracts)
Futures Volume: 9,370 contracts
Total Derivatives Value: ₹44,684 lakhs
Stock Price: ₹5,298 (intraday high ₹5,302)
1-Day Return: +2.65% (outperforming sector and Sensex)
Delivery Volume: 51.71k shares (-50.02% vs 5-day average)
Trading Liquidity: Supports trade size up to ₹1.52 crore

Investors should weigh these factors carefully when considering exposure to Alkem Laboratories in the current market environment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →